AT
NVCT icon

Avalon Trust’s Nuvectis Pharma NVCT Stock Holding History

Avalon Trust’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Hold
14,000
– – 0.02% 135
2026
Q1 		$108K Hold
14,000
– – 0.01% 209
2025
Q4 		$106K Buy
14,000
+4,000
+40% +$26.1K 0.01% 196
2025
Q3 		$60.2K Buy
+10,000
New +$68.7K ﹤0.01% 293

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Avalon Trust's NVCT Position: Q2 2026 in Review

Avalon Trust held its Nuvectis Pharma (NVCT) position steady in Q2 2026 at 14,000 shares worth $257K. The position accounts for 0.02% of the portfolio, ranked #135.

Avalon Trust first reported a position in NVCT in Q3 2025 and has held it in 4 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Avalon Trust held 14,000 shares of Nuvectis Pharma worth $257K as of Q2 2026.
  • Avalon Trust left its Nuvectis Pharma share count unchanged in Q2 2026.
  • Nuvectis Pharma made up 0.02% of Avalon Trust's portfolio in Q2 2026, its #135 holding.
  • Avalon Trust first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 4 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Avalon Trust's 13F filing for Q2 2026, filed 6 Aug 2026.